Comparative study on left-sided versus right-sided hepatectomy for resectable peri-hilar cholangiocarcinoma: a systematic review and meta-analysis

被引:0
作者
Bowen Xu
Wei Zhao
Jianhua Chang
Jinghua Yin
Nan Wang
Zhaoru Dong
Xuting Zhi
Tao Li
Zhiqiang Chen
机构
[1] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Hepatobiliary Surgery
[2] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Hepatobiliary Surgery, General Surgery
[3] Qilu Hospital,Department of Hepatobiliary Surgery, General Surgery
[4] Cheeloo College of Medicine,undefined
[5] Shandong University,undefined
[6] National Engineering Laboratory of Medical Implantable Devices,undefined
[7] Key Laboratory for Medical Implantable Devices of Shandong Province,undefined
[8] WEGO Holding Company Limited,undefined
[9] The Second Hospital of Shandong University,undefined
来源
World Journal of Surgical Oncology | / 21卷
关键词
Peri-hilar cholangiocarcinoma; Left-sided hepatectomy; Right-sided hepatectomy; Surgical strategy; Survival analysis; Prognosis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 127 条
[1]  
Khan SA(2002)Changing international trends in mortality rates for liver, biliary and pancreatic tumours J Hepatol 37 806-813
[2]  
Taylor-Robinson SD(2019)Classifications and misclassification in cholangiocarcinoma Liver Int 39 260-262
[3]  
Toledano MB(2013)Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections Ann Surg 258 129-140
[4]  
Beck A(2010)Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality J Hepatobiliary Pancreat Sci 17 455-462
[5]  
Elliott P(1992)Management strategies in resection for hilar cholangiocarcinoma Ann Surg 215 31-38
[6]  
Thomas HC(2021)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews J Clin Epidemiol 134 178-189
[7]  
Cardinale V(2017)AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both BMJ 358 790-799
[8]  
Nagino M(2021)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews Rev Esp Cardiol (Engl Ed) 74 16-1805
[9]  
Ebata T(2007)Practical methods for incorporating summary time-to-event data into meta-analysis Trials 8 135-444
[10]  
Yokoyama Y(2014)Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range BMC Med Res Methodol 14 1785-22